Doe v. Reed U.S. Supreme Court Amicus Brief for Free Speech Defense and Education Fund and Free Speech Coalition

Michael Harless Constitutional Law, U. S. Supreme Court

Today our firm filed an amicus brief for the Free Speech Defense and Education Fund, the Free Speech Coalition, and 28 other nonprofit and for profit organizations in the case of Doe v. Reed, in the United States Supreme Court.

The brief argues that, contrary to what the state of Washington claims,freedom of speech principles do indeed apply to the Washington state referendum petition process. Moreover, anonymity for referendum petition signers in that state legislative process is protected from state abridgment by the14th amendment as an individual privilege and immunity of United States citizenship secured under the republican form of government guarantee of Article IV, Section 4 of the United States Constitution. Read More

District of Columbia, et. al., v. Dick Anthony Heller Amicus Brief for Gun Owners of America, Inc., et. al.

Michael Harless Constitutional Law, Firearms Law, U. S. Supreme Court

Today, our firm filed an amicus curiae brief in the Supreme Court supporting the respondent in the D.C. gun ban case, District of Columbia, et. al., v. Dick Anthony Heller, No. 07-290. The brief was filed on behalf of Gun Owners of America, Inc., Gun Owners Foundation, Maryland Shall Issue, Inc., Virginia Citizens Defense League, Gun Owners of California, Inc., Lincoln Institute for Research and Education, and Conservative Legal Defense and Education Fund. Read More

Abigail Alliance Case — Amicus Brief Filed In U.S. Supreme Court for The Seniors Citizen League

Michael Harless Constitutional Law, Health Law, U. S. Supreme Court

Today we filed an amicus curiae brief in the Supreme Court in the case of Abigail Alliance v. VonEschenbach, Commissioner of the FDA.  The U.S. Supreme Court had been asked by an alliance of terminally ill patients with no conventional medical alternatives to overturn an en banc decision of the U.S. Court of Appeals for the D.C. Circuit which allows the FDA to bar these patients’ access to certain drugs, even after the FDA has approved them for Phase II testing. Read More